Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management - Centre de recherche des Cordeliers Accéder directement au contenu
Article Dans Une Revue Toxins Année : 2021

Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management

Résumé

Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome (STEC-HUS) is a form of thrombotic microangiopathy secondary to an infection by an enterohemorrhagic E. coli. Historically considered a pediatric disease, its presentation has been described as typical, with bloody diarrhea at the forefront. However, in adults, the clinical presentation is more diverse and makes the early diagnosis hazardous. In this review, we review the epidemiology, most important outbreaks, physiopathology, clinical presentation and prognosis of STEC-HUS, focusing on the differential features between pediatric and adult disease. We show that the clinical presentation of STEC-HUS in adults is far from typical and marked by the prevalence of neurological symptoms and a poorer prognosis. Of note, we highlight knowledge gaps and the need for studies dedicated to adult patients. The differences between pediatric and adult patients have implications for the treatment of this disease, which remains a public health threat and lack a specific treatment.
Fichier principal
Vignette du fichier
toxins-13-00306.pdf (557.34 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03215581 , version 1 (03-05-2021)

Identifiants

Citer

Benoit Travert, Cédric Rafat, Patricia Mariani, Aurélie Cointe, Antoine Dossier, et al.. Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management. Toxins, 2021, 13 (5), pp.306. ⟨10.3390/toxins13050306⟩. ⟨hal-03215581⟩
37 Consultations
86 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More